Sugi Predict

Sugi Predict / Compounds / SCHEMBL407871

SCHEMBL407871

SCHEMBL407871

CC(C)n1cc(I)c2c(Cl)ncnc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADK P55263 6/20 0.46
▸ SLC29A1 Q99808 1/20 0.41
▸ KDR P35968 7/20 0.39
▸ RET P07949 6/20 0.39
▸ CHEK1 O14757 1/20 0.38
▸ PIK3CD O00329 1/20 0.36
▸ PIK3CA P42336 1/20 0.36
▸ PIK3CB P42338 1/20 0.36
▸ PIK3CG P48736 1/20 0.36
▸ PRKDC P78527 1/20 0.36
▸ TEK Q02763 3/20 0.36
▸ SRC P12931 2/20 0.36
▸ LCK P06239 2/20 0.36
▸ ADORA2A P29274 1/20 0.36
▸ ADORA2B P29275 1/20 0.36
▸ ADORA1 P30542 1/20 0.36
▸ PI4KA P42356 1/20 0.36
▸ PI4K2B Q8TCG2 1/20 0.36
▸ PI4K2A Q9BTU6 1/20 0.36
▸ PI4KB Q9UBF8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30104030 0.89 ADK (0.43) ADKSLC29A1KDRRETCHEK1
SCHEMBL16236485 0.84 ADK (0.42) ADKSLC29A1KDRRETCHEK1
SCHEMBL16236551 0.83 ADK (0.41) ADKSLC29A1RETCHEK1SRC
SCHEMBL20162965 0.83 ADK (0.41) ADKSLC29A1CHEK1SRCMEN1
SCHEMBL30037220 0.83 ADK (0.41) ADKSLC29A1CHEK1SRCMEN1
SCHEMBL25611698 0.81 ADK (0.45) ADKKDRRETPIK3CDPIK3CA
SCHEMBL16236609 0.81 ADK (0.46) ADKSLC29A1CHEK1MEN1NR2F2
SCHEMBL1939924 0.80 ADK (0.46) ADKKDRRETPIK3CDPIK3CA
SCHEMBL1783992 0.80 PIK3CD (0.51) ADKKDRRETPIK3CDPIK3CA
SCHEMBL16236652 0.80 ADK (0.39) ADKSLC29A1CHEK1MEN1NR2F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577249-B2 GCN2 and perk kinase inhibitors and methods of use thereof DECIPHERA PHARMACEUTICALS, LLC (US) 2026-03-17 — — US disclosed
EP-4440703-A1 HETEROCYCLIC COMPOUNDS AS GCN2 AND PERK KINASE INHIBITORS Deciphera Pharmaceuticals, LLC (US) 2024-10-09 — — EP disclosed
CN-118715223-A Heterocyclic compounds as GCN2 and PERK kinase inhibitors 德西费拉制药有限责任公司 2024-09-27 — — CN disclosed
US-20240287081-A1 PERFLUOROALKANE SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDIN AND PYRROLO[2,3-D]PYRIMIDIN COMPOUNDS AND USES THEREOF ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2024-08-29 — — US disclosed
US-20240158394-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2024-05-16 — — US disclosed
WO-2024059200-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. (US) 2024-03-21 — — WO disclosed
US-11833153-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2023-12-05 — — US disclosed
US-20230382915-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-11-30 — — US disclosed
US-20230382915-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-11-30 — — US disclosed
US-20230382915-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-11-30 — — US disclosed
WO-2003000187-A2 NOVEL PYRAZOLO-AND PYRROLO-PYRIMIDINES AND USES THEREOF ARIAD PHARMACEUTICALS, INC. (US) 2003-01-03 — — WO disclosed
EP-1246829-A1 NOVEL HETEROCYCLES ARIAD PHARMACEUTICALS, INC. (US) 2002-10-09 — — EP disclosed
US-20020103161-A1 Novel heterocycles ARIAD PHARMACEUTICALS, INC. 2002-08-01 — — US disclosed
EP-1114052-A1 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 2001-07-11 — — EP disclosed
WO-2001044258-A1 NOVEL HETEROCYCLES ARIAD PHARMACEUTICALS, INC. (US) 2001-06-21 — — WO disclosed
CN-1259950-A Pyrrolo [2,3D] pyrimidines and their use as tyrosine kinase inhibitors BASF AG (DE) 2000-07-12 — — CN disclosed
WO-2000017202-A1 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 2000-03-30 — — WO disclosed
EP-0970084-A1 PYRROLO 2,3D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 2000-01-12 — — EP disclosed
US-6001839-A Substituted 4-amino-7H-pyrrolo [2,3,-d]-pyrimidines as PTK inhibitors BASF AKTIENGESELLSCHAFT (DE) 1999-12-14 — — US disclosed
WO-1998041525-A1 PYRROLO[2,3D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 1998-09-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577249-B2 GCN2 and perk kinase inhibitors and methods of use thereof EIF2AK4, GCN1, MAPKAPK2 ADK 315/4885SLC29A1 987/4885KDR 1705/4885
US-11833153-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors ATF4, MAP3K1, MAP3K6 ADK 361/4885SLC29A1 3337/4885KDR 2509/4885
US-20230382915-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF EIF2AK4, GCN1, EEF2K ADK 557/4885SLC29A1 3482/4885KDR 3973/4885
US-20020103161-A1 Novel heterocycles BMP2, SOST, BMP4 ADK 3097/4885SLC29A1 2104/4885KDR 730/4885
US-20240158394-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 ADK 208/4885SLC29A1 2182/4885KDR 4752/4885
US-20240287081-A1 PERFLUOROALKANE SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDIN AND PYRROLO[2,3-D]PYRIMIDIN COMPOUNDS AND USES THEREOF PPARD, PFAS, FOLR2 ADK 2762/4885SLC29A1 518/4885KDR 300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.